(08.01.22) – Kira Pharmaceuticals Appoints Angela Yan as President of China and Asia Development and Operations
(07.28.22) – Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
(11.12.21) – Kira Pharmaceuticals Appoints Teri Loxam as Chief Operating Officer and Chief Financial Officer
(02.22.21) – Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, China
(02.01.21) – Kira Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial for P014, a Bifunctional Biologic Medicine
(01.12.21) – Kira Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
(01.07.21) – Kira Pharmaceuticals Announces $53.5 Million Series B+ Financing to Advance LOGIC Drug Discovery Platform and Pipeline of Complement-targeted Therapies
(11.11.20) – Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
